Acumen Pharmaceuticals earnings were -$116.3M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest ABOS earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$28.8M, down 22.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ABOS reported annual earnings of -$102.3M, with 95.4% growth.
Acumen Pharmaceuticals Earnings Reports & History FAQ
What were Acumen Pharmaceuticals's earnings last quarter?
On ABOS's earnings call on Invalid Date, Acumen Pharmaceuticals (NASDAQ: ABOS) reported Q1 2025 earnings per share (EPS) of -$0.48, up 92% year over year. Total ABOS earnings for the quarter were -$28.80 million. In the same quarter last year, Acumen Pharmaceuticals's earnings per share (EPS) was -$0.25.
Is Acumen Pharmaceuticals profitable or losing money?
As of the last Acumen Pharmaceuticals earnings report, Acumen Pharmaceuticals is currently losing money. Acumen Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$116.25 million, a 107.83% increase year over year.
What was ABOS's earnings growth in the past year?
As of Acumen Pharmaceuticals's earnings date in Invalid Date, Acumen Pharmaceuticals's earnings has grown year over year. ABOS earnings in the past year totalled -$116.25 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.